that wasn’t CLTX, it was another CAR-T which was licensed to a US biotech, can’t recall the name off the top of my head. But I’ll put it up once I remember.
the biotech who licensed it found the result was a bit hard to replicate, so it goes to show how hard GBM is to treat. So much is unknown.
which is why CLTX is so exciting, as it is going about tackling GBM in a totally new way that has strong credentials based on its natural ability to bind to GBM cells.
CHM Price at posting:
32.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)